Get the Daily Brief
Latest Biotech News
PCSK9’s second act: Antibodies, editing and a Verve buy that rewrites playbook
PCSK9 — long a validated target for cholesterol lowering via monoclonal antibodies and siRNA — is reemerging as a focal point for gene‑editing strategies after Eli Lilly’s acquisition of Verve...
T‑cell expansion signature could predict immunotherapy response — single‑cell TCR work
Researchers at Tokyo University of Science published a pan‑immunotherapy gene signature that predicts intratumoral CD8+ T‑cell clonal expansion, using multi‑site tumor mouse models and...
Novo main backer forces boardroom purge — chair to step down
The Novo Nordisk shareholder behind the company’s foundation has pushed out more than half of the drugmaker’s board, triggering an executive shake-up at the maker of obesity drug Wegovy. The move...
10x sues Illumina: patent fight targets single-cell expansion
10x Genomics filed two patent lawsuits against Illumina alleging infringement tied to sequencing and single-cell/spatial technologies as it seeks to broaden its product portfolio. The complaints,...
Grail pulls $325M — bankroll to support commercialization and FDA push
Grail secured about $325 million in a private placement to fund commercial expansion, reimbursement efforts and its planned regulatory push for multi-cancer early detection tests. The financing...
FDA accepts Replimune resubmission — review clock set for April
Replimune announced that the U.S. FDA has accepted its resubmitted biologics license application for RP1 in advanced melanoma and set a target decision date of April 10, 2026. The filing adds...
Exelixis to file NDA after Phase 3 OS win — colorectal combo trims mortality
Exelixis said detailed STELLAR-303 results show its oral TKI zanzalintinib combined with Roche’s Tecentriq reduced risk of death by about 20% versus standard therapy in previously treated...
AI arms race in life sciences... new models and lab partnerships accelerate discovery
Anthropic launched a life-sciences–focused model and inked collaborations to let researchers query biological datasets in plain English, signaling Big Tech’s deeper push into drug discovery and...
CDMOs take center stage — capacity and capability strain in cell & gene era
Industry analysis and company moves underscore a pivot: contract development and manufacturing organizations (CDMOs) are now strategic partners for cell and gene therapy scale-up. Reports stress...
Single-cell signature predicts CD8+ T cell bursts — a potential biomarker for immunotherapy
Researchers using single-cell RNA and TCR sequencing in longitudinal mouse tumor models identified a conserved gene expression 'expansion signature' that predicts CD8+ T cell clonal bursts prior...
CAR T cells target HIV-linked B cell cancers — new antigen strategy
Researchers reported development of CAR T cells engineered to target antigens associated with HIV-linked B cell malignancies, offering a tailored cell therapy strategy for a distinct subset of...
Hologic to be taken private — Blackstone, TPG agree up to $18.3B deal
Private-equity firms Blackstone and TPG agreed to acquire Hologic in a transaction valued at up to $18.3 billion, offering $76 per share plus up to $3 in contingent value rights tied to...
Multiplex T‑cell programming: Integrated epigenetic–genetic platform reported
Researchers published an integrated platform that combines targeted epigenetic edits with multiplexed genetic engineering to reprogram primary human T cells, reporting enhanced functional profiles...
Grail raises $325M: Financing extends commercial and reimbursement push
Cancer early‑detection company Grail said it has agreed a private placement expected to raise roughly $325 million to support commercial expansion and reimbursement efforts. The financing includes...
Replimune resubmission accepted: FDA sets April 2026 review date
The FDA has accepted Replimune’s resubmission for RP1, the company’s oncolytic herpes‑based biologic for advanced melanoma, and set a regulatory decision date of April 10, 2026. Replimune said the...
Exelixis presses NDA after survival win: zanzalintinib data detailed
Exelixis plans an NDA filing for zanzalintinib after detailed STELLAR‑303 data showed an overall survival benefit when combined with Roche’s atezolizumab in previously treated metastatic...
Multiomics push... Illumina ramps roadmap as Element touts single‑run platform
Illumina executives outlined progress on the company’s multiomics strategy at ASHG, saying roadmap technologies will be market‑ready next year as the firm integrates proteomics, single‑cell and...
CRISPR vs prime editing: Company claims spark public dispute
CRISPR Therapeutics publicly described a new gene‑editing tool as “a significant advance” over prime editing, prompting a rebuttal from Prime Medicine and sparking debate across the gene‑editing...
10x sues Illumina: Single‑cell and spatial patents in the dock
10x Genomics has filed a lawsuit alleging that Illumina infringes patents covering single‑cell and spatial transcriptomics technologies. The complaint follows a pattern of aggressive IP...
ADCs keep deal flow hot — Aimedbio’s near‑$1B pact and ESMO buzz
Deal activity in the antibody‑drug conjugate (ADC) space continued as Aimedbio struck a near‑$1 billion licensing agreement with Boehringer Ingelheim for a preclinical solid‑tumor ADC candidate,...